Intelligence Search Intelligence Filter by: Industry Team Airport & AviationAutomotiveEmerging TechnologiesEnergy Food & BeverageHealth CareHospitality, Resort & GolfInsurance & Reinsurance Life SciencesMedical DevicesSports Practice Area Business Law All Business LawEmployee Benefits & Executive CompensationEnvironmental RegulationEstates & TrustsFinance & Financial InstitutionsHealth Care Finance Private Equity & Venture CapitalPublic FinanceReal EstateSecurities, Commodities & Exchange RegulationTaxationTransactional & Securities Government & Public Policy All Government & Public PolicyFDA RegulatoryGovernment ProcurementImmigration, Nationality & Consular Law NHTSA & Motor Vehicle SafetyPolitical LawPublic PolicySurface Transport Intellectual Property All Intellectual PropertyBusiness Method & Software PatentsChemical, Biotechnology & PharmaceuticalElectronicsGreen Energy TechnologiesInformation Technology & Outsourcing IP Due DiligenceIP LitigationMechanical & Electromechanical TechnologiesPatent Office TrialsTrademark, Copyright & Advertising Counseling International All InternationalChina EuropeJapan Litigation All LitigationAntitrustAppellateBankruptcy & Business ReorganizationsBusiness Litigation & Dispute ResolutionConstructionConsumer Financial Services Distribution & FranchiseGovernment Enforcement, Compliance & White Collar DefenseInsurance & Reinsurance LitigationLabor & EmploymentPrivacy, Security & Information ManagementSecurities Enforcement & LitigationTrade Secret Noncompete Litigation Topic Accountable Care OrganizationsAmerica Invents Act (Patent Reform)Consumer Protection Act Corporate GovernanceDodd–Frank Wall Street ReformExport Control/Economic Sanctions Foreign Corrupt Practices Act (FCPA)Health Care ReformPersonalized Medicine Type ArticleBlog Post BookNewsletter VideoWhite Paper Featured All Filters applied: Search phrase entered: Sort results by: Most Recent Most Viewed Most Shared Foley Blogs: CFSL Bulletin Cleantech & Nano Dashboard Insights Labor & Employment Law Perspectives Personalized Medicine Bulletin PharmaPatents Renewable Energy Outlook Wisconsin Appellate Law previous23456next How FDA Differs From CMS in Clinical Lab Test Oversight 14 March 2013 Law360 Partner Antoinette Konski authored an article that appeared in Law360 on March 14, 2013 titled "How FDA Differs From CMS In Clinical Lab Test Oversight." Federal Circuit Finds Obviousness-Type Double Patenting Without Common Ownership 12 March 2013 PharmaPatents Obviousness-type double patenting usually arises between commonly-owned patents or patent applications. While the USPTO has interpreted the judicially-created doctrine... Does The Experimental Use Exception Survive The AIA? 07 March 2013 PharmaPatents Now that the March 16, 2013 effective date of the first-to-file provisions of the Leahy-Smith America Invents Act (AIA) is fast-approaching, I have been reviewing... USPTO to Waive New Appeal Fee for Appeal Briefs Filed by March 18, 2013 05 March 2013 PharmaPatents While most stakeholders are focused on the first-inventor-to-file changes to U.S. patent law that take effect on March 16, 2013, some applicants could realize significant... Results From Early PTAB Decisions on Inter Partes Review Petitions 04 March 2013 Based on a review of early results of PTAB's decisions on inter partes reviews, IP Litigation Partner and Chair of Foley's Patent Office Trials Practice Matthew... Urgent: Time Flying in 2013 as First-to-File and New Fee Systems Now Arriving! 04 March 2013 Cleantech & Nano An updated URGENT alert that the new U.S. first-to-file patent reform laws are now less than two weeks away. Many companies, whether nanotech, cleantech, biotech,... Supreme Court Holds a Gunn to Exclusive Federal Court Jurisdiction Over Patent Malpractice Claims 28 February 2013 PharmaPatents In Gunn v. Minton, the Supreme Court held that federal courts do not have exclusive jurisdiction over patent malpractice claims. Under 28 USC § 1338(a), federal... Federal Circuit Upholds Fentora Patents, But Affirms Non-Infringement 26 February 2013 PharmaPatents In Cephalon, Inc. v. Watson Pharmaceuticals, Inc., the Federal Circuit reversed the district court’s finding that two Orange Book-listed patents for Cephalon’s FENTORA®... USPTO Fee Reductions for Expedited Examination Effective March 19, 2013 22 February 2013 Legal News Alert: Intellectual Property On March 19, 2013, expediting examination will become less expensive as the USPTO lowers fees from $4,800 to $4,000 for the Track 1 prioritized examination program.... Maximizing the Effect of Patent Applications as Prior Art Under the AIA 21 February 2013 PharmaPatents Now that we are less than one month away from implementation of the First-Inventor-To-File provisions of the America Invents Act (AIA), stakeholders are considering... previous23456next Related 1 2 3
How FDA Differs From CMS in Clinical Lab Test Oversight 14 March 2013 Law360 Partner Antoinette Konski authored an article that appeared in Law360 on March 14, 2013 titled "How FDA Differs From CMS In Clinical Lab Test Oversight."
Federal Circuit Finds Obviousness-Type Double Patenting Without Common Ownership 12 March 2013 PharmaPatents Obviousness-type double patenting usually arises between commonly-owned patents or patent applications. While the USPTO has interpreted the judicially-created doctrine...
Does The Experimental Use Exception Survive The AIA? 07 March 2013 PharmaPatents Now that the March 16, 2013 effective date of the first-to-file provisions of the Leahy-Smith America Invents Act (AIA) is fast-approaching, I have been reviewing...
USPTO to Waive New Appeal Fee for Appeal Briefs Filed by March 18, 2013 05 March 2013 PharmaPatents While most stakeholders are focused on the first-inventor-to-file changes to U.S. patent law that take effect on March 16, 2013, some applicants could realize significant...
Results From Early PTAB Decisions on Inter Partes Review Petitions 04 March 2013 Based on a review of early results of PTAB's decisions on inter partes reviews, IP Litigation Partner and Chair of Foley's Patent Office Trials Practice Matthew...
Urgent: Time Flying in 2013 as First-to-File and New Fee Systems Now Arriving! 04 March 2013 Cleantech & Nano An updated URGENT alert that the new U.S. first-to-file patent reform laws are now less than two weeks away. Many companies, whether nanotech, cleantech, biotech,...
Supreme Court Holds a Gunn to Exclusive Federal Court Jurisdiction Over Patent Malpractice Claims 28 February 2013 PharmaPatents In Gunn v. Minton, the Supreme Court held that federal courts do not have exclusive jurisdiction over patent malpractice claims. Under 28 USC § 1338(a), federal...
Federal Circuit Upholds Fentora Patents, But Affirms Non-Infringement 26 February 2013 PharmaPatents In Cephalon, Inc. v. Watson Pharmaceuticals, Inc., the Federal Circuit reversed the district court’s finding that two Orange Book-listed patents for Cephalon’s FENTORA®...
USPTO Fee Reductions for Expedited Examination Effective March 19, 2013 22 February 2013 Legal News Alert: Intellectual Property On March 19, 2013, expediting examination will become less expensive as the USPTO lowers fees from $4,800 to $4,000 for the Track 1 prioritized examination program....
Maximizing the Effect of Patent Applications as Prior Art Under the AIA 21 February 2013 PharmaPatents Now that we are less than one month away from implementation of the First-Inventor-To-File provisions of the America Invents Act (AIA), stakeholders are considering...